JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
about
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humansJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisJakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseTargeting JAK2 in the therapy of myeloproliferative neoplasmsSOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibitionRuxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrowCombination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cellsTranslating advances from the basic biology of aging into clinical applicationAntagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesSuppression of cytokine signaling: the SOCS perspective.Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.Targeting the Th17 pathway in psoriasis.Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.STAT signaling in the pathogenesis and treatment of myeloid malignancies.The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.Jak1-STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis.JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition.Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma
P2860
Q21133609-072B89EE-2933-41C6-ADAA-5F654C95335AQ24186554-B1FB614A-83AC-4E7C-847D-BCC75BCABFBCQ24201893-C6C5CFEE-1DC1-46D4-95B0-57461F2E20D5Q24617270-2CF4F0A1-7C9A-42E2-B7DA-45BA857960FEQ26860796-6027DDFD-C315-4C53-932B-DE199ECB07AEQ27676669-99F6182F-EF14-498A-BAE3-667EC1C42CA2Q33405766-C2DF1492-FC8D-4586-9182-3BFF2CC6E3BEQ34021753-F45E3105-CD93-44B9-8B89-EABC182F862EQ34337681-1F0E8DB9-3449-4EE2-A12A-B701B2E9A18AQ35571892-228197B5-D44E-4F82-8494-B7E257EAC968Q36318162-D970BF71-9FD3-4B35-A690-F4B95B259AC6Q36528628-16598029-7905-4E30-BAF8-61AEEB74A44DQ37169105-79C8C7E4-257E-4569-8EE8-1C82C2BF394DQ37278469-9D9B4A8C-8128-4C1D-8957-C6BF4D96BEB4Q37377109-DD9A1AE2-D245-4E3F-A8AA-AA05909A4631Q38042048-4C8674A0-5FC0-4C10-932F-9A43AFB24488Q38042734-40CFDCC3-3009-4561-9446-78C8E00755D6Q38140880-514C4369-22CE-482F-AD8F-70D8B4CE8AC9Q38687571-453E03C2-FDBB-4AA7-83D7-97C8F817DD8FQ38756741-A8C0FFCD-D291-4BA3-A20A-8D28F6F9BFD3Q47099145-FA1CC4B3-783A-4AA0-8949-7D1A1FAB20FCQ47422451-0015F281-758E-4866-A7B6-98C4D4305D10Q54496230-BFC35ACB-8A73-4B79-8AAA-4E11D7671D57Q58690869-CA24D52A-FE0E-4307-9B30-9DA64365F7B5
P2860
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
@ast
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
@en
type
label
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
@ast
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
@en
prefLabel
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
@ast
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
@en
P1433
P1476
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
@en
P2093
A Pardanani
P304
P356
10.1016/J.BLRE.2011.06.002
P577
2011-07-13T00:00:00Z